Chikungunya Outbreak in Mayotte
The Centers for Disease Control and Prevention (CDC) has issued a Level 2 travel health alert for Mayotte due to an active chikungunya outbreak. Mayotte, a French overseas collectivity located in the Comoros Archipelago off the east coast of Africa, is experiencing sustained transmission of chikungunya virus.
About Chikungunya
Chikungunya is a viral infection transmitted primarily through the bite of infected Aedes mosquitoes, particularly Aedes aegypti and Aedes albopictus. The disease causes fever, joint pain, muscle aches, headache, and rash. While severe complications are uncommon, joint pain can persist for weeks to months in some patients.
Risk and Transmission
Travelers to Mayotte face elevated exposure risk during the outbreak period. Mosquito transmission is most active in warm, humid conditions, typically in tropical and subtropical regions. Humans are the primary reservoir for chikungunya virus during epidemics.
Preventive Measures for Travelers
- Mosquito bite prevention: Use EPA-registered insect repellents containing DEET, picaridin, IR3535, oil of lemon eucalyptus, para-menthane-diol, or 2-undecanone
- Protective clothing: Wear long sleeves, pants, socks, and closed-toe shoes, especially during dawn and dusk when mosquitoes are most active
- Environmental controls: Use air conditioning, window/door screens, bed nets, and mosquito coils in accommodations
- Timing awareness: Limit outdoor activity during peak mosquito hours (early morning and evening)
When to Seek Care
If you develop fever, joint pain, or rash within 3–14 days after potential exposure, seek medical attention and inform healthcare providers of your travel history to Mayotte.
Pharmacist's note: There is no specific antiviral treatment or vaccine for chikungunya. Management is supportive, focusing on symptom relief through NSAIDs for pain and fever, fluid intake, and rest. Travelers should ensure they have adequate supplies of over-the-counter pain relievers compatible with their medical history. Antimalarial prophylaxis may be indicated depending on individual risk factors—consult a travel medicine specialist before departure. Pregnant women and immunocompromised individuals should discuss travel plans with their healthcare provider.
Recommended Actions
- Consult a travel medicine clinician 4–6 weeks before travel
- Purchase comprehensive travel health insurance
- Stay informed on current outbreak status via CDC travel notices
- Register with your embassy if traveling